Azilsartan kamedoxomil is a pharma-grade active pharmaceutical ingredient supplied as the potassium salt of the medoxomil ester of azilsartan. The molecular formula is C₃₀H₂₃KN₄O₈, the nominal molecular weight is 606.62 g/mol, and the CAS registry number is 863031-24-7. The material is manufactured under current good manufacturing practice aligned with ICH Q7 and 21 CFR 210/21 CFR 211. The API is specified for oral solid dosage forms—immediate-release tablet, capsule, and granule—and for injectable dosage forms when the grade is ordered with reduced bioburden and bacterial endotoxin controls. Because azilsartan kamedoxomil is a low-aqueous-solubility prodrug, pharmaceutical formulation design must address particle-size reduction, powder rheology, and pH-dependent dissolution rather than simple blending. The product is supplied as oral non-micronized, oral micronized, and parenteral low-endotoxin grades; each grade is defined by particle-size specification, solvent profile, impurity profile, and bioburden rather than by a single compendial model number. The regulatory starting material is the final crystallized potassium salt, while subsequent micronization and packaging are executed under primary manufacturing controls.

What Particle-Size and Powder-Rheology Parameters Govern Oral Solid Dosage Performance?

Particle-size distribution is the principal physical attribute controlling dissolution rate and content uniformity in low-dose azilsartan kamedoxomil tablets. Oral-grade material is commonly micronized and controlled by laser diffraction per USP General Chapter 429. A representative acceptance range is D90 ≤ 45 µm and D50 5–15 µm; tighter limits may be imposed when direct compression is required because excessive fines below 5 µm can increase segregation and sticking. Bulk density is typically controlled at 0.35–0.55 g/cm³, tapped density at 0.50–0.75 g/cm³, Hausner ratio 1.20–1.40, and Carr index 15–28 for material destined to high-shear granulation. In a 65 L high-shear granulator followed by fluid-bed drying with inlet air temperature 50–60 °C, granule loss on drying is maintained NMT 2.0% w/w to limit sticking and hydrolytic degradation of the medoxomil ester. Direct compression without particle engineering is generally unsuitable because the potassium salt exhibits cohesive flow and low bulk density. Roller compaction with roll pressure between 4 MPa and 8 MPa may be required when a dry-granulation route is selected. Published industrial batch records for this specific API are limited, so process limits should be confirmed during development and scale-up.

On a dosator-type capsule filling machine, powder bridging and fill-weight variability are observed when Carr index exceeds 35 or angle of repose exceeds 40°. A tamping-pin machine is less sensitive to flow but may produce ejection-force variability if the powder bed contains fines below 10 µm above 20% w/w. For the 40 mg and 80 mg dose strengths, the active ingredient is typically pre-blended with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate. Geometric dilution is required because the active-fill portion is low-dose and potent. Granule presentations for sachet or stick-pack filling are often manufactured by top-spray fluid-bed granulation using a povidone K30 binder solution at 2–5% w/w of dry granulate. Moisture content is controlled NMT 2.0% w/w before lubrication. Dissolution testing for oral solid dosage forms follows USP General Chapter 711; because azilsartan kamedoxomil is practically insoluble in 0.1 N HCl, a two-stage dissolution method with a pH 6.8 phosphate buffer stage and 0.05% sodium lauryl sulfate may be required to achieve discriminating conditions. Published data for this specific API configuration are limited; therefore, dissolution apparatus selection and sinker use must be verified during analytical method development.

Specification Limits, Residual Solvents, and Elemental Impurities

The release specification for pharma-grade azilsartan kamedoxomil aligns with ICH Q3A(R2) for related substances, ICH Q3C(R8) for residual solvents, and ICH Q3D(R2) for elemental impurities. Because the maximum daily dose is 80 mg, the qualification threshold for unspecified degradation products is 0.15% or 1.0 mg/day; the reporting threshold is 0.05%. Residual solvent limits are assigned according to the actual manufacturing route and must not exceed the Class 2 options specified in ICH Q3C(R8). If methanol is used in the final crystallization, the limit is NMT 3000 ppm; if dichloromethane is used, NMT 600 ppm. Elemental impurities are controlled on the basis of ICH Q3D(R2) permitted daily exposure values rather than arbitrary ppm limits. For oral products the PDEs are As 15 µg/day, Pb 5 µg/day, Cd 2 µg/day, and Hg 30 µg/day; for parenteral products the PDEs are As 15 µg/day, Pb 5 µg/day, Cd 2 µg/day, and Hg 3 µg/day.

When Injectable-Grade Material Is Required, How Are Microbial and Particulate Control Established?

Azilsartan kamedoxomil potassium is handled as an injectable-grade API only when the manufacturing site has established parenteral-grade controls. The potassium salt improves wetting in aqueous matrices relative to the free acid, but the medoxomil prodrug has poor equilibrium solubility in neutral and acidic media; parenteral formulation therefore requires a pH-controlled or co-solvent system after dissolution and aseptic filtration. The dry API is not a sterile material, and terminal sterilization of the dry powder is not appropriate because of the risk of ester hydrolysis and particle aggregation. Injectable-grade release includes reduced bioburden, typically NMT 10 CFU/g, and bacterial endotoxin control by Ph.Eur 2.6.14 or USP General Chapter 85. The endotoxin limit is derived from the maximum intravenous bolus dose and the patient weight; a fixed API limit of NMT 0.050 EU/mg is a common starting point but must be re-evaluated for the final clinical dose. Subvisible particulate testing of the reconstituted solution should follow USP General Chapter 788; for small-volume parenterals, the acceptance criterion is NMT 6000 particles/container at ≥ 10 µm and NMT 600 particles/container at ≥ 25 µm. Published data for the injectable route of azilsartan kamedoxomil are limited; therefore, filter compatibility, stopper leachables, and light stability must be qualified during pharmaceutical development.

Equivalent Dose Adjustments Follow from CYP-Independent Ester Hydrolysis

Azilsartan kamedoxomil differs from losartan potassium, candesartan cilexetil, and valsartan in several clinically relevant properties. After oral administration, the medoxomil ester is hydrolyzed by esterases to azilsartan, the active AT1 receptor antagonist. Unlike losartan, activation does not require CYP2C9- or CYP3A4-mediated oxidation, reducing the potential for drug interactions with azole antifungals and other CYP inhibitors. The absolute oral bioavailability of azilsartan kamedoxomil is approximately 60%; peak plasma concentration occurs at 1.5–3 h; protein binding exceeds 99%; and elimination half-life is approximately 11 h. At 80 mg once daily, azilsartan kamedoxomil produced greater 24-h systolic blood pressure reductions than valsartan 320 mg and candesartan 32 mg in randomized registration trials. Compared with candesartan cilexetil, the medoxomil ester is chemically distinct; both are ester prodrugs, but azilsartan kamedoxomil is supplied as a potassium salt, which may assist pH-controlled dissolution in weak alkaline media. Compared with valsartan, which is not a prodrug, azilsartan has slower dissociation from the AT1 receptor in in vitro binding studies. The potassium salt contributes approximately 6.45% elemental potassium by mass; a 80 mg dose therefore supplies approximately 5.2 mg of potassium, which is clinically negligible for most patients but relevant in hyperkalemia risk assessment.

For late-phase and commercial manufacture, the API should be stored in a tight, light-resistant container at controlled room temperature 20–25 °C with excursions 15–30 °C and protected from moisture. Retest periods are assigned from stability data generated per ICH Q1A(R2); photostability testing per ICH Q1B is required because the medoxomil ester can undergo photolytic degradation in solution. Oral-grade packaging typically consists of low-density polyethylene bags inside aluminum-laminated foil, while injectable-grade material is subdivided in an ISO 7 environment with additional outer packaging. Pre-drying of the API is recommended if storage relative humidity exceeds 60% before blending; water uptake above 1.0% w/w can promote ester hydrolysis. Users should avoid processing with strongly alkaline granulating fluids above pH 9 in aqueous systems because ester hydrolysis accelerates at alkaline pH; acid granulation below pH 2 may likewise promote degradation. Incompatibilities include oxidizing agents and strong bases, which should not be used as direct excipients unless compatibility has been shown by stress studies.